Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Stomach Neoplasms 1Solid Tumors 1Solid Cancers 1Skin Diseases 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

binimetinib 2ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Spironolactone 1Paclitaxel 1Low-Level Light Therapy 1Leuprolide 1Fluorouracil 1Everolimus 1Equipment and Supplies 1Dacarbazine 1Cetuximab 1Cantharidin 1BF-200 ALA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Skin Diseases × ipatasertib × Clear all
NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
242 enrolled 12 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡